Kineta Announces Restructuring and Exploration of Strategic . . . SEATTLE, Feb 29, 2024 — Kineta, Inc (Nasdaq: KA), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistance, announced today that it has completed a review of its business, including the status of its programs, resources and capabilities Following this review, Kineta is implementing a significant corporate
Pipeline - Kineta Inc. Kineta is building next-generation immunotherapies to address the major challenges with current cancer treatments We aim to improve outcomes for cancer patients by solving the problems of cancer resistance Our novel drug programs are focused on addressing and correcting immuno-suppression, exhausted T-cells and poor tumor immunogenicity
Kineta Provides Update on its Ongoing Phase 1 2 VISTA-101 Clinical . . . For more information on Kineta, please visit www kinetabio com, and follow Kineta on Twitter, LinkedIn and Facebook KVA12123 is a VISTA blocking immunotherapy in development as a twice weekly monoclonal antibody infusion drug being evaluated in a Phase 1 2 clinical trial for patients with advanced solid tumors
Kineta Completes Reverse Merger with Yumanity Therapeutics Shares of Kineta to commence trading on Nasdaq under new ticker symbol “KA” on December 19, 2022 Seattle, WA — (December 19, 2022) Kineta, Inc (“Kineta” or the “Company”), a clinical-stage biotechnology company focused on developing next-generation immunotherapies to address cancer immune resistance, announced today the completion of its reverse merger with Yumanity Therapeutics
Kineta to Receive $5 Million Milestone Payment from Merck SEATTLE, June 29, 2023 — (June 29, 2023) Kineta, Inc (Nasdaq: KA), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistance, announced today the achievement of a development milestone which triggers a $5 million payment from its research and development collaboration with Merck (known as MSD outside the
Kineta Announces Reverse Merger with NASDAQ-listed Yumanity . . . Yumanity Therapeutics announces definitive agreements for two strategic transactions Yumanity Therapeutics, Inc to sell its clinical-stage product candidate YTX-7739 as well as its unpartnered discovery-stage neuroscience product candidates and targets to Janssen Pharmaceutica NV in a $26 million cash transaction Kineta, Inc , a private immuno-oncology company, to merge with Yumanity in an
Kineta Announces First Patient Dosed in Phase 1 2 VISTA-101 Clinical . . . SEATTLE, Oct 17, 2023 — Kineta, Inc (Nasdaq: KA), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistance, announced today that the first patient has been dosed in Part B of its Phase 1 2 VISTA-101 clinical trial that will evaluate the safety and
Kineta Appoints Keith Baker as Chief Financial Officer Kineta Appoints Keith Baker as Chief Financial Officer Seattle, WA — (October 4, 2022) Kineta, Inc (“Kineta” or the “Company”), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology, announced today the appointment of Keith Baker as the Company’s new Chief Financial Officer (CFO)
KVA12123 Clears Additional Cohorts in Monotherapy and in . . . - Kineta Inc. For more information on Kineta, please visit www kinetabio com, and follow Kineta on X (Twitter) and LinkedIn KVA12123 is a VISTA blocking immunotherapy in development as a twice weekly monoclonal antibody infusion drug being evaluated in a Phase 1 2 clinical trial for patients with advanced solid tumors